PR Newswire BiotechOriginal article
Resolve Therapeutics Completes Enrollment in Phase 2 Study of RSLV-132 in Sjögren's Disease
Phase 2RSLV-132Positive
AI Analysis
Summary
Resolve Therapeutics completed enrollment of approximately 110 participants in a Phase 2 randomized, double-blind, placebo-controlled study of RSLV-132 for Sjögren's Disease, with topline results expected in Q2 2027.
Clinical Trial Data
Phase
Phase 2
Patients
110
Outcome Details
Enrollment completed; topline results expected Q2 2027
Importance:6/10
Sentiment:
0.50
clinical trialenrollment completionPhase 2Sjögren's Diseaseimmunology
Read the original article
Published by PR Newswire Biotech on October 7, 2026 1:45 PM